Raymond James Trust’s AbbVie ABBV Stock Holding History

Raymond James Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$32.6M	Sell	165,181 -3,012	-2%	-$562K	0.71%	29
2024 Q2	$28.8M	Buy	168,193 +6,347	+4%	+$1.05M	0.68%	30
2024 Q1	$29.5M	Sell	161,846 -1,205	-0.7%	-$208K	0.71%	29
2023 Q4	$25.3M	Sell	163,051 -11,679	-7%	-$1.7M	0.67%	33
2023 Q3	$26M	Buy	174,730 +138	+0.1%	+$20.3K	0.77%	28
2023 Q2	$23.5M	Sell	174,592 -2,318	-1%	-$340K	0.68%	30
2023 Q1	$28.2M	Buy	176,910 +3,315	+2%	+$507K	0.89%	19
2022 Q4	$28.1M	Sell	173,595 -35	-0%	-$5.37K	0.94%	20
2022 Q3	$23.3M	Buy	173,630 +3,520	+2%	+$505K	0.87%	22
2022 Q2	$26.1M	Sell	170,110 -13,154	-7%	-$2.01M	0.93%	19
2022 Q1	$29.7M	Sell	183,264 -4,858	-3%	-$706K	0.91%	20
2021 Q4	$25.5M	Sell	188,122 -9,306	-5%	-$1.1M	0.76%	27
2021 Q3	$21.3M	Sell	197,428 -672	-0.3%	-$76.8K	0.71%	33
2021 Q2	$22.3M	Buy	198,100 +24,363	+14%	+$2.74M	0.74%	29
2021 Q1	$18.8M	Buy	173,737 +3,507	+2%	+$375K	0.66%	37
2020 Q4	$18.2M	Buy	170,230 +4,580	+3%	+$440K	0.7%	31
2020 Q3	$14.5M	Sell	165,650 -613	-0.4%	-$57.7K	0.63%	40
2020 Q2	$16.3M	Sell	166,263 -726	-0.4%	-$63.9K	0.79%	27
2020 Q1	$12.7M	Buy	166,989 +4,215	+3%	+$359K	0.75%	30
2019 Q4	$14.4M	Sell	162,774 -1,236	-0.8%	-$103K	0.69%	31
2019 Q3	$12.4M	Buy	164,010 +2,156	+1%	+$148K	0.64%	35
2019 Q2	$11.8M	Sell	161,854 -1,897	-1%	-$149K	0.65%	36
2019 Q1	$13.2M	Buy	163,751 +2,601	+2%	+$213K	0.76%	25
2018 Q4	$14.9M	Buy	161,150 +3,070	+2%	+$270K	0.96%	21
2018 Q3	$15M	Buy	158,080 +1,591	+1%	+$151K	0.84%	24
2018 Q2	$14.5M	Sell	156,489 -934	-0.6%	-$91.2K	0.88%	23
2018 Q1	$14.9M	Sell	157,423 -9,675	-6%	-$1.06M	1.03%	19
2017 Q4	$16.2M	Sell	167,098 -4,872	-3%	-$459K	1.09%	17
2017 Q3	$15.3M	Sell	171,970 -3,084	-2%	-$235K	1.09%	16
2017 Q2	$12.7M	Buy	175,054 +7,535	+4%	+$507K	0.95%	19
2017 Q1	$10.9M	Buy	167,519 +10,787	+7%	+$678K	0.83%	24
2016 Q4	$9.81M	Buy	156,732 +14,331	+10%	+$875K	0.78%	27
2016 Q3	$8.98M	Buy	142,401 +6,772	+5%	+$438K	0.77%	26
2016 Q2	$8.4M	Buy	135,629 +2,999	+2%	+$183K	0.74%	31
2016 Q1	$7.58M	Buy	132,630 +15,071	+13%	+$840K	0.71%	31
2015 Q4	$6.96M	Buy	117,559 +15,019	+15%	+$865K	0.64%	38
2015 Q3	$5.58M	Buy	102,540 +3,687	+4%	+$240K	0.63%	42
2015 Q2	$6.64M	Sell	98,853 -2,492	-2%	-$163K	0.7%	37
2015 Q1	$5.93M	Buy	101,345 +1,887	+2%	+$114K	0.64%	39
2014 Q4	$6.51M	Sell	99,458 -2,593	-3%	-$163K	0.7%	37
2014 Q3	$5.89M	Buy	102,051 +1,104	+1%	+$61.3K	0.67%	37
2014 Q2	$5.7M	Buy	100,947 +1,052	+1%	+$55.2K	0.65%	40
2014 Q1	$5.13M	Sell	99,895 -10,097	-9%	-$510K	0.63%	39
2013 Q4	$5.81M	Buy	109,992 +16,075	+17%	+$790K	0.76%	27
2013 Q3	$4.2M	Buy	93,917 +1,267	+1%	+$56.2K	0.65%	32
2013 Q2	$3.83M	Buy	+92,650	New	+$4.05M	0.63%	33

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Raymond James Trust's ABBV Position: Q3 2024 in Review

Raymond James Trust reduced its AbbVie (ABBV) stake by 1.8% in Q3 2024, selling an estimated $562K and leaving 165,181 shares worth $32.6M. The position accounts for 0.71% of the portfolio, ranked #29.

Raymond James Trust first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Raymond James Trust held 165,181 shares of AbbVie worth $32.6M as of Q3 2024.
Raymond James Trust sold 3,012 AbbVie shares in Q3 2024, an estimated $562K.
AbbVie made up 0.71% of Raymond James Trust's portfolio in Q3 2024, its #29 holding.
Raymond James Trust first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.